Ferric maltol real-world effectiveness study in hospital practice (FRESH) is published in BMJ Open Gastro.- Shield Therapeutics.

Shield Therapeutics plc notes the recent publication in BMJ Open Gastroenterology, titled: “Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK.” The study details the positive results from a real-world study using ferric maltol to assess clinical characteristics and outcomes of patients with inflammatory bowel disease (IBD) receiving ferric maltol for iron-deficiency anaemia in the UK (FRESH Study). The observational, multicentre study, retrospective cohort study included adults with IBD and iron-deficiency anaemia (IDA) and who also had serum ferritin levels below 30 ?g/L or transferrin saturation below 20%, who received ferric maltol. The study concluded that ferric maltol increases haemoglobin and iron indices and is generally well tolerated in patients with IBD and IDA treated in clinical practice. These real-world data confirm the favourable benefit/risk balance findings from randomised control trials. See- "Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK"- http://orcid.org/0000-0002-9659-3247JR. Fraser Cummings, Aileen Fraser, Catherine Stansfield, Ian Beales, Shaji Sebastian, Sami Hoque. K. BMJ Open Gastro 2021;8:e000530. doi:10.1136/. bmjgast-2020-000530. .